Transcript CLICK AND TYPE TITLE HERE

Supply of OPV
by
M/s RITES
Twenty Fourth Meeting
Of
the India Expert Advisory Group (IEAG)
for Polio Eradication
on
15th March 2012
By S N Panda
GM/Rites
Outline of Presentation
•
•
•
•
•
Introduction
Procurement Objective
Supply overview
Our Experience
Recommendation
Introduction
• M/s RITES Limited(A PSU under Ministry of Rlys)
assisting the Department of Health & Family Welfare as
Procurement Agent for procurement of OPVs funded
by External Agencies like World Bank since May’ 2010
previously handled by UNICEF
• In FY 2010-11 five indents were processed for four
types of vaccines like bOPV, tOPV,mOPV1 and mOPV3
• In FY 2011-12 two indents were processed for two
types of vaccines like bOPV and tOPV only
• In FY 2012-13 one indent is already processed for bOPV
(Supply in April – June 2012)
Vaccine Supply Objectives
To ensure a sustained and uninterrupted supply
of quality vaccines
Through
• WHO Prequalification
• Appropriate contracting
Supply of OPV
FY
OPV
Indent Qty
(Million Doses)
Procured Qty
Reasons for short
(Million Doses) procurement
2010-11
bOPV
162
100
tOPV
471
247
bOPV
275
275
tOPV
450
109*
No offer /No
responsive
offer/conditional
offer
bOPV
340
238
No offer /No
responsive offer for
short notice supply
bOPV
300
tOPV
450
Procurement
Plan under
approval
2011-12
2012-13
No offer /No
responsive offer
*One of the bidder’s manufacturing process was taken on
review by WHO during decision process
Response From Suppliers in 2011-12
OPV
Number of
prequalified Firms
Number of
Participated Firms
Remarks
bOPV
6
3
Only Indian
suppliers
participated
tOPV
6
3
One foreign
supplier
participated
Installed Capacity of OPV Suppliers
(Participated in RITES Tender)
Firm Name
Installed Capacity
Million Doses per annum
M/s Panacea Biotec
1600
M/s Haffkine
600
M/s Sanofi Pasture
4000
M/s Bharat Biotech
1382
Our OPV Procurement Experience
• 50% of qualified suppliers participated in Bid
• Mostly suppliers from India participated
though it was a LIB except M/s Sanofi from
France
• No offer for full Bid quantity
• Appreciable gap in offered price of different
suppliers
Reasons for low response
• Demand- Supply gap
• Shortage of bulk in International market
• Non participation of foreign suppliers due to
(i) supply of OPV in short notice
(ii) shelf life of minimum 18 months on the
date of arrival at port of entry in India
(iii) Marking of “CGS Not for Sale” on primary
packaging
OPV Requirement for 2012-13 rounds
OPV
Indent Qty
(Million Doses)
bOPV
Total
tOPV
Total
Delivery
Requirement
50
31/08/2012
100
28/02/2013
50
31/03/2013
100
31/05/2013
300
225
31/12/2012
225
31/01/2013
450
Remarks
Procurement Plan
Under Approval
Recommendation of RITES
• Indent should be sent at least 12 months in
advance with respect to supply requirement
so that tender can be finalised six months
prior to requirements. This implies advanced
planning
and
long
term
IEAG
recommendations.
• Residual Shelf Life of vaccine at the time of
supply as per Indian Drug & Cosmetic Act
(i.e. 60% of total life of 24 months) instead of
18 months
• Waiver of “CGS Not for Sale” on primary
packaging
Thank You